Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

The objective of this session is to learn about the latest developments on the use of broadly neutralizing antibodies against HIV. This session is addressed to scientists and clinicians concerned with the feasibility, applicability and effectiveness of broadly neutralizing antibodies to prevent HIV infection or establish long-term control of the virus replication. The audience is presented the latest discoveries in the field of HIV broadly neutralizing antibodies in both primates and humans, to highlight the challenges related to their use, as well as the opportunities and hopes these tools offer to the response to HIV.

11:00
TUSY0201
Introduction
11:05
TUSY0202
Determinants of bnAbs development in humans
Roger Kouyos, Switzerland
11:15
TUSY0203
Translational development of PGT121 and PGDM1400
Dan Barouch, United States
11:25
TUSY0204
bNabs and partial control of cell-associated SHIV infection
Stephen Kent, Australia
11:35
TUSY0205
bnAbs to prevent mother to child transmission (MTCT)
Lynne Mofenson, United States
Slides
11:45
TUSY0206
Questions and answers
12:25
TUSY0207
Closing remarks